Drug Profile
Research programme: myxopyronins - Roche
Alternative Names: Myxopyronin A; Myxopyronin BLatest Information Update: 21 Feb 2017
Price :
$50
*
At a glance
- Originator Anadys Pharmaceuticals; Boston University
- Class Antibacterials; Lactones
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 03 Aug 2007 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 14 Jun 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 25 May 1998 Preclinical development for Bacterial infections in USA (Unknown route)